Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts
What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)? Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, be...
Gespeichert in:
| Veröffentlicht in: | Reproductive biomedicine online 2021-08, Vol.43 (2), p.205-214 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 2 |
| container_start_page | 205 |
| container_title | Reproductive biomedicine online |
| container_volume | 43 |
| creator | Legrand, Charlotte Keller, Laura Collinet, Pierre Barbotin, Anne Laure Béhal, Hélène Rubod, Chrystele Decanter, Christine |
| description | What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)?
Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma (‘endometrioma’) and dermoid, mucinous or serous cyst (‘other cysts’).
A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the ‘endometrioma’ and ‘other cysts’ groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred.
Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies. |
| doi_str_mv | 10.1016/j.rbmo.2021.04.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04477131v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1472648321001966</els_id><sourcerecordid>2550632672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-19eefce0cbc54b984fd3dc6c28941446a2afb5e33cb700188a4020c1924e34ff3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EoqXwBzggH0Fig782HxKXqgKKtFIvcLYcZ9z1KomXsROUX8FfxlHKHrnY1swz73jmJeQtZwVnvPx0KrAdQiGY4AVTBRPsGbnmqhK7UjX8-eVdyyvyKsYTY7xmtXxJrqQSqmrq5pr8eQh2SUCNtdMw9Sb5MFIXkDrA5HufFnpGiIDzlvIj_R0GyKdPR9rC6B9HGmaD3ow0TUOYMG45Q48-poALDW7VmH2YIo0TPgIuH2lulvy5B5p79SYHqV1iiq_JC2f6CG-e7hvy8-uXH3f3u8PDt-93t4edVVKlHW8AnAVmW7tXbVMr18nOllbUjeJKlUYY1-5BSttW69i1UXk9ljdCgVTOyRvyYdM9ml6f0Q8GFx2M1_e3B73GmFJVxSWfeWbfb-wZw68JYtKDjxb63oyQZ9Jiv2elFGUlMio21GKIEcFdtDnTq2n6pFfT9Gpa7qHzr3LRuyf9qR2gu5T8cykDnzcA8kZmD6ij9TBa6DyCTboL_n_6fwGpT6uz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2550632672</pqid></control><display><type>article</type><title>Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Legrand, Charlotte ; Keller, Laura ; Collinet, Pierre ; Barbotin, Anne Laure ; Béhal, Hélène ; Rubod, Chrystele ; Decanter, Christine</creator><creatorcontrib>Legrand, Charlotte ; Keller, Laura ; Collinet, Pierre ; Barbotin, Anne Laure ; Béhal, Hélène ; Rubod, Chrystele ; Decanter, Christine</creatorcontrib><description>What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)?
Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma (‘endometrioma’) and dermoid, mucinous or serous cyst (‘other cysts’).
A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the ‘endometrioma’ and ‘other cysts’ groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred.
Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies.</description><identifier>ISSN: 1472-6483</identifier><identifier>ISSN: 1472-6491</identifier><identifier>EISSN: 1472-6491</identifier><identifier>DOI: 10.1016/j.rbmo.2021.04.020</identifier><identifier>PMID: 34247989</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Benign ovarian tumors ; Cohort Studies ; Cryopreservation - methods ; Cystadenoma, Mucinous - complications ; Cystadenoma, Mucinous - epidemiology ; Cystadenoma, Mucinous - pathology ; Cystadenoma, Mucinous - therapy ; Cystadenoma, Serous - complications ; Cystadenoma, Serous - epidemiology ; Cystadenoma, Serous - pathology ; Cystadenoma, Serous - therapy ; Endometriomas ; Endometriosis - complications ; Endometriosis - epidemiology ; Endometriosis - pathology ; Endometriosis - therapy ; Female ; Fertility preservation ; Fertility Preservation - methods ; Fertility Preservation - statistics & numerical data ; Gynecologic Surgical Procedures - rehabilitation ; Gynecologic Surgical Procedures - statistics & numerical data ; Humans ; Life Sciences ; Oocyte Retrieval - methods ; Oocyte Retrieval - statistics & numerical data ; Oocyte vitrification ; Ovarian Cysts - complications ; Ovarian Cysts - epidemiology ; Ovarian Cysts - pathology ; Ovarian Cysts - therapy ; Ovarian Neoplasms - complications ; Ovarian Neoplasms - epidemiology ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Ovarian Reserve - physiology ; Ovary - surgery ; Ovulation Induction - methods ; Ovulation Induction - statistics & numerical data ; Pregnancy ; Retrospective Studies ; Teratoma - complications ; Teratoma - epidemiology ; Teratoma - pathology ; Teratoma - therapy ; Treatment Outcome ; Young Adult</subject><ispartof>Reproductive biomedicine online, 2021-08, Vol.43 (2), p.205-214</ispartof><rights>2021 Reproductive Healthcare Ltd.</rights><rights>Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-19eefce0cbc54b984fd3dc6c28941446a2afb5e33cb700188a4020c1924e34ff3</citedby><cites>FETCH-LOGICAL-c434t-19eefce0cbc54b984fd3dc6c28941446a2afb5e33cb700188a4020c1924e34ff3</cites><orcidid>0000-0002-3824-572X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rbmo.2021.04.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34247989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04477131$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Legrand, Charlotte</creatorcontrib><creatorcontrib>Keller, Laura</creatorcontrib><creatorcontrib>Collinet, Pierre</creatorcontrib><creatorcontrib>Barbotin, Anne Laure</creatorcontrib><creatorcontrib>Béhal, Hélène</creatorcontrib><creatorcontrib>Rubod, Chrystele</creatorcontrib><creatorcontrib>Decanter, Christine</creatorcontrib><title>Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts</title><title>Reproductive biomedicine online</title><addtitle>Reprod Biomed Online</addtitle><description>What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)?
Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma (‘endometrioma’) and dermoid, mucinous or serous cyst (‘other cysts’).
A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the ‘endometrioma’ and ‘other cysts’ groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred.
Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies.</description><subject>Adult</subject><subject>Benign ovarian tumors</subject><subject>Cohort Studies</subject><subject>Cryopreservation - methods</subject><subject>Cystadenoma, Mucinous - complications</subject><subject>Cystadenoma, Mucinous - epidemiology</subject><subject>Cystadenoma, Mucinous - pathology</subject><subject>Cystadenoma, Mucinous - therapy</subject><subject>Cystadenoma, Serous - complications</subject><subject>Cystadenoma, Serous - epidemiology</subject><subject>Cystadenoma, Serous - pathology</subject><subject>Cystadenoma, Serous - therapy</subject><subject>Endometriomas</subject><subject>Endometriosis - complications</subject><subject>Endometriosis - epidemiology</subject><subject>Endometriosis - pathology</subject><subject>Endometriosis - therapy</subject><subject>Female</subject><subject>Fertility preservation</subject><subject>Fertility Preservation - methods</subject><subject>Fertility Preservation - statistics & numerical data</subject><subject>Gynecologic Surgical Procedures - rehabilitation</subject><subject>Gynecologic Surgical Procedures - statistics & numerical data</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Oocyte Retrieval - methods</subject><subject>Oocyte Retrieval - statistics & numerical data</subject><subject>Oocyte vitrification</subject><subject>Ovarian Cysts - complications</subject><subject>Ovarian Cysts - epidemiology</subject><subject>Ovarian Cysts - pathology</subject><subject>Ovarian Cysts - therapy</subject><subject>Ovarian Neoplasms - complications</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Ovarian Reserve - physiology</subject><subject>Ovary - surgery</subject><subject>Ovulation Induction - methods</subject><subject>Ovulation Induction - statistics & numerical data</subject><subject>Pregnancy</subject><subject>Retrospective Studies</subject><subject>Teratoma - complications</subject><subject>Teratoma - epidemiology</subject><subject>Teratoma - pathology</subject><subject>Teratoma - therapy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1472-6483</issn><issn>1472-6491</issn><issn>1472-6491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EoqXwBzggH0Fig782HxKXqgKKtFIvcLYcZ9z1KomXsROUX8FfxlHKHrnY1swz73jmJeQtZwVnvPx0KrAdQiGY4AVTBRPsGbnmqhK7UjX8-eVdyyvyKsYTY7xmtXxJrqQSqmrq5pr8eQh2SUCNtdMw9Sb5MFIXkDrA5HufFnpGiIDzlvIj_R0GyKdPR9rC6B9HGmaD3ow0TUOYMG45Q48-poALDW7VmH2YIo0TPgIuH2lulvy5B5p79SYHqV1iiq_JC2f6CG-e7hvy8-uXH3f3u8PDt-93t4edVVKlHW8AnAVmW7tXbVMr18nOllbUjeJKlUYY1-5BSttW69i1UXk9ljdCgVTOyRvyYdM9ml6f0Q8GFx2M1_e3B73GmFJVxSWfeWbfb-wZw68JYtKDjxb63oyQZ9Jiv2elFGUlMio21GKIEcFdtDnTq2n6pFfT9Gpa7qHzr3LRuyf9qR2gu5T8cykDnzcA8kZmD6ij9TBa6DyCTboL_n_6fwGpT6uz</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Legrand, Charlotte</creator><creator>Keller, Laura</creator><creator>Collinet, Pierre</creator><creator>Barbotin, Anne Laure</creator><creator>Béhal, Hélène</creator><creator>Rubod, Chrystele</creator><creator>Decanter, Christine</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-3824-572X</orcidid></search><sort><creationdate>202108</creationdate><title>Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts</title><author>Legrand, Charlotte ; Keller, Laura ; Collinet, Pierre ; Barbotin, Anne Laure ; Béhal, Hélène ; Rubod, Chrystele ; Decanter, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-19eefce0cbc54b984fd3dc6c28941446a2afb5e33cb700188a4020c1924e34ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Benign ovarian tumors</topic><topic>Cohort Studies</topic><topic>Cryopreservation - methods</topic><topic>Cystadenoma, Mucinous - complications</topic><topic>Cystadenoma, Mucinous - epidemiology</topic><topic>Cystadenoma, Mucinous - pathology</topic><topic>Cystadenoma, Mucinous - therapy</topic><topic>Cystadenoma, Serous - complications</topic><topic>Cystadenoma, Serous - epidemiology</topic><topic>Cystadenoma, Serous - pathology</topic><topic>Cystadenoma, Serous - therapy</topic><topic>Endometriomas</topic><topic>Endometriosis - complications</topic><topic>Endometriosis - epidemiology</topic><topic>Endometriosis - pathology</topic><topic>Endometriosis - therapy</topic><topic>Female</topic><topic>Fertility preservation</topic><topic>Fertility Preservation - methods</topic><topic>Fertility Preservation - statistics & numerical data</topic><topic>Gynecologic Surgical Procedures - rehabilitation</topic><topic>Gynecologic Surgical Procedures - statistics & numerical data</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Oocyte Retrieval - methods</topic><topic>Oocyte Retrieval - statistics & numerical data</topic><topic>Oocyte vitrification</topic><topic>Ovarian Cysts - complications</topic><topic>Ovarian Cysts - epidemiology</topic><topic>Ovarian Cysts - pathology</topic><topic>Ovarian Cysts - therapy</topic><topic>Ovarian Neoplasms - complications</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Ovarian Reserve - physiology</topic><topic>Ovary - surgery</topic><topic>Ovulation Induction - methods</topic><topic>Ovulation Induction - statistics & numerical data</topic><topic>Pregnancy</topic><topic>Retrospective Studies</topic><topic>Teratoma - complications</topic><topic>Teratoma - epidemiology</topic><topic>Teratoma - pathology</topic><topic>Teratoma - therapy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Legrand, Charlotte</creatorcontrib><creatorcontrib>Keller, Laura</creatorcontrib><creatorcontrib>Collinet, Pierre</creatorcontrib><creatorcontrib>Barbotin, Anne Laure</creatorcontrib><creatorcontrib>Béhal, Hélène</creatorcontrib><creatorcontrib>Rubod, Chrystele</creatorcontrib><creatorcontrib>Decanter, Christine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Reproductive biomedicine online</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Legrand, Charlotte</au><au>Keller, Laura</au><au>Collinet, Pierre</au><au>Barbotin, Anne Laure</au><au>Béhal, Hélène</au><au>Rubod, Chrystele</au><au>Decanter, Christine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts</atitle><jtitle>Reproductive biomedicine online</jtitle><addtitle>Reprod Biomed Online</addtitle><date>2021-08</date><risdate>2021</risdate><volume>43</volume><issue>2</issue><spage>205</spage><epage>214</epage><pages>205-214</pages><issn>1472-6483</issn><issn>1472-6491</issn><eissn>1472-6491</eissn><abstract>What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)?
Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma (‘endometrioma’) and dermoid, mucinous or serous cyst (‘other cysts’).
A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the ‘endometrioma’ and ‘other cysts’ groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred.
Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34247989</pmid><doi>10.1016/j.rbmo.2021.04.020</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3824-572X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-6483 |
| ispartof | Reproductive biomedicine online, 2021-08, Vol.43 (2), p.205-214 |
| issn | 1472-6483 1472-6491 1472-6491 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04477131v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Benign ovarian tumors Cohort Studies Cryopreservation - methods Cystadenoma, Mucinous - complications Cystadenoma, Mucinous - epidemiology Cystadenoma, Mucinous - pathology Cystadenoma, Mucinous - therapy Cystadenoma, Serous - complications Cystadenoma, Serous - epidemiology Cystadenoma, Serous - pathology Cystadenoma, Serous - therapy Endometriomas Endometriosis - complications Endometriosis - epidemiology Endometriosis - pathology Endometriosis - therapy Female Fertility preservation Fertility Preservation - methods Fertility Preservation - statistics & numerical data Gynecologic Surgical Procedures - rehabilitation Gynecologic Surgical Procedures - statistics & numerical data Humans Life Sciences Oocyte Retrieval - methods Oocyte Retrieval - statistics & numerical data Oocyte vitrification Ovarian Cysts - complications Ovarian Cysts - epidemiology Ovarian Cysts - pathology Ovarian Cysts - therapy Ovarian Neoplasms - complications Ovarian Neoplasms - epidemiology Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Ovarian Reserve - physiology Ovary - surgery Ovulation Induction - methods Ovulation Induction - statistics & numerical data Pregnancy Retrospective Studies Teratoma - complications Teratoma - epidemiology Teratoma - pathology Teratoma - therapy Treatment Outcome Young Adult |
| title | Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A49%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oocyte%20accumulation%20for%20fertility%20preservation%20in%20women%20with%20benign%20ovarian%20tumours%20with%20a%20history%20of%20previous%20surgery,%20multiple%20or%20large%20cysts&rft.jtitle=Reproductive%20biomedicine%20online&rft.au=Legrand,%20Charlotte&rft.date=2021-08&rft.volume=43&rft.issue=2&rft.spage=205&rft.epage=214&rft.pages=205-214&rft.issn=1472-6483&rft.eissn=1472-6491&rft_id=info:doi/10.1016/j.rbmo.2021.04.020&rft_dat=%3Cproquest_hal_p%3E2550632672%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2550632672&rft_id=info:pmid/34247989&rft_els_id=S1472648321001966&rfr_iscdi=true |